Currently out of the existing stock ratings of Emily Bodnar, 63 are a BUY (90%), 7 are a HOLD (10%).

Emily Bodnar

Work Performance Price Targets & Ratings Chart

Analyst Emily Bodnar works at HC WAINWRIGHT with a stock forecast success ratio of 22.23% fulfilled within 54.53 days on average.

Emily Bodnar’s has documented 132 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NVCR, Novocure Ltd at 22-Feb-2024.

Wall Street Analyst Emily Bodnar

Analyst best performing recommendations are on RNAZ (TRANSCODE THERAPEUTICS).
The best stock recommendation documented was for RNAZ (TRANSCODE THERAPEUTICS) at 10/24/2023. The price target of $3 was fulfilled within 84 days with a profit of $2.57 (597.67%) receiving and performance score of 71.15.

Average potential price target upside

DICE Dice Molecules Holdings LLC FEMY Femasys NVCR Novocure Ltd OLMA Olema Pharmaceuticals VTYX Ventyx Biosciences SQZ Sqz Biotechnologies Co ACLX Arcellx BCTX Briacell Therapeutics Corp CNTX Context Therapeutics GRCL Gracell Biotechnologies . INKT Mink Therapeutics IOBT IO Biotech NKTX Nkarta  RNAZ Transcode Therapeutics AGEN Agenus

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

48

$0.45 (0.95%)

48

6 months 15 days ago

1/8 (12.5%)

$0.45 (0.95%)

85

Hold

56

7 months 29 days ago

0/1 (0%)

$27.35 (95.46%)

Hold

48

$0.45 (0.95%)

68

8 months 4 days ago

1/3 (33.33%)

$1.56 (3.36%)

27

Hold

48

$0.45 (0.95%)

38

8 months 4 days ago

1/2 (50%)

$1.56 (3.36%)

27

Hold

48

$0.45 (0.95%)

71

8 months 4 days ago

0/2 (0%)

$1.56 (3.36%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Emily Bodnar is most bullish on?

Potential upside of $14.52 has been obtained for BCTX (BRIACELL THERAPEUTICS CORP)

Which stock is Emily Bodnar is most reserved on?

Potential downside of -$0.5 has been obtained for ACLX (ARCELLX)

What Year was the first public recommendation made by Emily Bodnar?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?